Skip to main content

Breyanzi Side Effects

Generic name: lisocabtagene maraleucel

Medically reviewed by Drugs.com. Last updated on Jul 12, 2022.

Note: This document contains side effect information about lisocabtagene maraleucel. Some dosage forms listed on this page may not apply to the brand name Breyanzi.

Applies to lisocabtagene maraleucel: intravenous suspension.

Warning

Intravenous route (Suspension)

Warning: Cytokine Release Syndrome and Neurologic ToxicitiesCytokine release syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving lisocabtagene maraleucel. Do not administer lisocabtagene maraleucel to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab with or without corticosteroids.Neurologic toxicities, including fatal or life-threatening reactions, occurred in patients receiving lisocabtagene maraleucel, including concurrently with CRS, after CRS resolution, or in the absence of CRS. Monitor for neurological events after treatment with lisocabtagene maraleucel. Provide supportive care and/or corticosteroids as needed.Lisocabtagene maraleucel is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Breyanzi® REMS.

Serious side effects of Breyanzi

Along with its needed effects, lisocabtagene maraleucel (the active ingredient contained in Breyanzi) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking lisocabtagene maraleucel:

More common

  • Agitation
  • back pain
  • bleeding gums
  • bloody urine
  • blurred vision
  • body aches or pain
  • burning, numbness, tingling, or painful sensations
  • chest pain
  • chills
  • coma
  • confusion
  • cough
  • coughing up blood
  • decrease frequency or amount of urine
  • diarrhea
  • difficulty swallowing
  • dizziness
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • drowsiness
  • ear congestion
  • fast, pounding, or irregular heartbeat or pulse
  • fever
  • hallucinations
  • headache
  • hives, itching
  • holding false beliefs that cannot be changed by fact
  • increased menstrual flow or vaginal bleeding
  • increased thirst
  • irritability
  • loss of appetite
  • loss of voice
  • lower back or side pain
  • mood or mental changes
  • muscle or bone pain
  • muscle spasm, tenderness, twitching, jerking, wasting, or weakness
  • nausea
  • nosebleeds
  • painful or difficult urination
  • paralysis
  • pounding in the ears
  • problems with speech or speaking
  • prolonged bleeding from cuts
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • red or black, tarry stools
  • red or dark brown urine
  • runny or stuffy nose
  • seizures
  • shakiness and unsteady walk
  • shakiness in the legs, arms, hands, or feet
  • skin rash
  • slow or fast heartbeat
  • sneezing
  • sore throat
  • stiff neck
  • stomach pain
  • sweating
  • trembling and shaking of the hands or feet
  • trouble breathing
  • ulcers, sores, or white spots in the mouth
  • unsteadiness, awkwardness, trembling, or other problems with muscle control or coordination
  • unusual bleeding or bruising
  • unusual excitement, nervousness, or restlessness
  • unusual tiredness or weakness
  • vomiting
  • weight gain

Other side effects of Breyanzi

Some side effects of lisocabtagene maraleucel may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Constipation
  • tenderness, pain, swelling, warmth, skin discoloration, and prominent superficial veins at the injection site
  • trouble sleeping

For Healthcare Professionals

Applies to lisocabtagene maraleucel: intravenous suspension.

Hematologic

Very common (10% or more): Lymphopenia (94%), neutropenia (81%), leukopenia (77%), anemia (58%), thrombocytopenia (54%), febrile neutropenia (37%), bleeding episodes (31%), international normalized ratio increased (13%)

Common (1% to 10%): Histiocytosis lymphocytic hemophagocytosis, coagulopathy, activated partial thromboplastin time prolonged[Ref]

Hypersensitivity

Frequency not reported: Hypersensitivity/anaphylaxis[Ref]

Immunologic

Very common (10% or more): Cytokine release syndrome (79%), Grade 3 and Grade 4 hypofibrinogenemia with Grade 3 and 4 CRS (16%), hypogammaglobulinemia (e.g., hypogammaglobulinemia, immunoglobulins decreased, blood immunoglobulin G decreased, blood immunoglobulin A decreased, blood immunoglobulin M decreased) (43%), infections pathogen unspecified (41%), viral infections (26%), bacterial infections (19%), fungal infections (13%)

Common (1% to 10%): Graft versus host disease

Frequency not reported: Immunogenicity[Ref]

Musculoskeletal

Very common (10% or more): Myalgia (15%), arthralgia (12%), back pain/pain in extremity (10%)

Common (1% to 10%): Muscle spasms[Ref]

Metabolic

Very common (10% or more): Decreased appetite (37%), hypophosphatemia (24%), edema (e.g., face edema, generalized edema, localized edema, edema peripheral) (21%), hypokalemia (12%), hyponatremia (11%), weight loss (11%), fluid overload (10%)

Common (1% to 10%): Tumor lysis syndrome[Ref]

Psychiatric

Very common (10% or more): Delirium (21%), anxiety (13%), sleep disorders/insomnia/nightmare (10%)[Ref]

Hepatic

Very common (10% or more): Acute kidney injury (e.g., acute kidney injury, anuria, azotemia, renal failure, renal tubular dysfunction, renal tubular necrosis, blood creatinine increased) (24%), increased alanine aminotransferase (21%), increased bilirubin (21%)

Oncologic

Frequency not reported: Secondary malignancies/cancer recurrence[Ref]

Respiratory

Very common (10% or more): Hypoxia (24%), cough/productive cough (21%), dyspnea/respiratory distress/respiratory failure (16%), pulmonary edema (16%), tachypnea (12%), pleural effusion (10%), nasal congestion (10%)

Common (1% to 10%): Respiratory distress, respiratory failure, acute respiratory distress syndrome, oropharyngeal pain[Ref]

Other

Very common (10% or more): Fatigue/malaise (48%), pyrexia (40%), increased aspartate aminotransferase (28%), hypokalemia (27%), hypophosphatemia pain (18%), fever (16%), chills (12%)

Common (1% to 10%): Multiple organ dysfunction syndrome[Ref]

General

Serious adverse reactions occurred in 46% of patients. The most common nonlaboratory, serious adverse reactions (2% or greater) were CRS, encephalopathy, sepsis, febrile neutropenia, aphasia, pneumonia, fever, hypotension, dizziness, and delirium. Fatal adverse reactions occurred in 4% of patients.[Ref]

Nervous system

Very common (10% or more): Headache/migraine (30%), encephalopathy (e.g., encephalopathy, cognitive disorder, confusional state, depressed level of consciousness, disturbance in attention, lethargy, mental status changes, somnolence, automatism) (29%), delirium (e.g., delirium, agitation, hallucination, hallucination visual, irritability, restlessness) (21%), peripheral neuropathy (11%)

Common (1% to 10%): Tremor, dizziness, seizure, speech disorder/aphasia/dysarthria, motor dysfunction[Ref]

Renal

Very common (10% or more): Acute kidney injury (24%)[Ref]

Cardiovascular

Very common (10% or more): Hypotension (26%), tachycardia/sinus tachycardia (25%)

Common (1% to 10%): Disseminated intravascular coagulation, cardiac arrest, cardiac failure, capillary leak syndrome, thrombosis[Ref]

Dermatologic

Very common (10% or more): Rash/rash maculopapular/rash papular/rash pruritic (16%)[Ref]

Gastrointestinal

Very common (10% or more): Nausea (33%), diarrhea (26%), constipation (23%), vomiting (21%), abdominal pain (21%)[Ref]

Ocular

Common (1% to 10%): Visual impairment[Ref]

References

1. "Product Information. Breyanzi (lisocabtagene maraleucel)." Bristol-Myers Squibb (2021):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.